Cytori Therapeutics (CYTX) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Fed’s Jefferson sees no urgency for another rate increase
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Cytori Reports Q3 2018 Business and Financial Results
November 14, 2018 4:15 PM ESTSAN DIEGO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (Cytori or the Company) today announced Q3 2018 financial results and provided updates on corporate activities.Â
Q3 2018 net loss was $2.3 million, or $0.27 per share. Operating cash burn for Q3 was approximately $2.6 million. Cytori ended Q3 with approximately $6.8 million of cash and cash equivalents.
Cytori is developing its lead chemotherapy drug, ATI-0918, a generic version... More
